{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+the+Circulatory+System&page=6",
    "query": {
      "condition": "Diseases of the Circulatory System",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 3302,
    "total_pages": 331,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+the+Circulatory+System&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+the+Circulatory+System&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T17:36:35.373Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01031173",
      "title": "Treatment Protocol of Replagal for Patients With Fabry Disease",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "agalsidase alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031173"
    },
    {
      "nct_id": "NCT07049783",
      "title": "Examining the Circadian Timing Effects of the Hypotensive Response to Exercise",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Young Adults",
        "Hypertension",
        "Post-Exercise Hypotension",
        "Circadian Rhythm"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Freda Patterson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-07-22",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 1,
      "location_summary": "Newark, Delaware",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07049783"
    },
    {
      "nct_id": "NCT05938127",
      "title": "Impact of Respiratory Training in Lymphoma Survivors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Inspiratory muscle strength training",
          "type": "DEVICE"
        },
        {
          "name": "Sham Inspiratory muscle strength training",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1,
      "start_date": "2024-09-16",
      "completion_date": "2024-12-09",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05938127"
    },
    {
      "nct_id": "NCT06560502",
      "title": "Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcer",
        "Venous Leg Ulcer",
        "Ulcer Foot",
        "Leg Ulcer"
      ],
      "interventions": [
        {
          "name": "Standard of Care-DFU",
          "type": "OTHER"
        },
        {
          "name": "AmnioCore - DFU",
          "type": "OTHER"
        },
        {
          "name": "Amnio Quad-Core - DFU",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care-VLU",
          "type": "OTHER"
        },
        {
          "name": "Amnio Tri-Core - VLU",
          "type": "OTHER"
        },
        {
          "name": "Amniocore Pro +",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Stability Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-08-01",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 1,
      "location_summary": "Circleville, Ohio",
      "locations": [
        {
          "city": "Circleville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06560502"
    },
    {
      "nct_id": "NCT05732402",
      "title": "An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Immunoglobulin A Nephropathy",
        "Membranous Nephropathy",
        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "Povetacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alpine Immune Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2023-03-15",
      "completion_date": "2028-03-02",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Valencia",
          "state": "California"
        },
        {
          "city": "Arvada",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05732402"
    },
    {
      "nct_id": "NCT01825473",
      "title": "Study of Erythromycin in GER-Associated Apnea of the Newborn",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastroesophageal Reflux",
        "Apnea",
        "Bradycardia"
      ],
      "interventions": [
        {
          "name": "Erythromycin",
          "type": "DRUG"
        },
        {
          "name": "Multi-channel intra-luminal impedance (MII) pH monitoring",
          "type": "DEVICE"
        },
        {
          "name": "Placebo (D5W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Days and older"
      },
      "enrollment_count": 40,
      "start_date": "2012-09",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2013-04-05",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01825473"
    },
    {
      "nct_id": "NCT05775094",
      "title": "A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoporosis",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Romosozumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-03-07",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05775094"
    },
    {
      "nct_id": "NCT00940095",
      "title": "Clazosentan in Aneurysmal Subarachnoid Hemorrhage",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Clazosentan 5 m/h",
          "type": "DRUG"
        },
        {
          "name": "Clazosentan 15 mg/h",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 577,
      "start_date": "2009-07-01",
      "completion_date": "2011-01-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-09",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 29,
      "location_summary": "Glendale, California • San Francisco, California • Stanford, California + 21 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00940095"
    },
    {
      "nct_id": "NCT00403481",
      "title": "An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "olmesartan medoxomil",
          "type": "DRUG"
        },
        {
          "name": "Olmesartan medoxomil plus Hydrochlorothiazide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2006-11",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-03",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403481"
    },
    {
      "nct_id": "NCT03108066",
      "title": "MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL Gene Mutation",
        "VHL",
        "VHL Syndrome",
        "VHL Gene Inactivation",
        "Von Hippel",
        "Von Hippel-Lindau Disease",
        "Von Hippel's Disease",
        "Von Hippel-Lindau Syndrome, Modifiers of",
        "Clear Cell Renal Cell Carcinoma",
        "Clear Cell RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "MK-3795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-04-24",
      "completion_date": "2023-09-27",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-10-10T17:36:35.373Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108066"
    }
  ]
}